

Edgar Filing: INNOVATIVE MEDICAL SERVICES - Form 10QSB/A

INNOVATIVE MEDICAL SERVICES
Form 10QSB/A
August 07, 2003

U.S. Securities and Exchange Commission
Washington, D.C. 20549

FORM 10-QSB/A

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the period ended October 31, 2001

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 [No Fee Required]
For the transition period from _____ to

Commission File number 0-21019

INNOVATIVE MEDICAL SERVICES

(Name of small business issuer in its charter)

California

33-0530289

(State or other jurisdiction of incorporation or
organization)

(IRS Employer
Identification No.)

1725 Gillespie Way, El Cajon, California 92020

(Address of principal executive offices)

619 596 8600

Issuer's telephone number

Check whether the issuer (1) filed all reports to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

State the number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date: 7,678,099 as of December 14, 2001.

Explanatory note on amendment

Edgar Filing: INNOVATIVE MEDICAL SERVICES - Form 10QSB/A

The Registrant has filled this amendment to reflect changes made to its financial statements for the fiscal year ended July 31, 2002 with respect to the writing off of certain start up costs which had been previously capitalized. The Amendment revises and replaces the following sections:

Item 1. Financial Statements and Notes to Financial Statements

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations;

The interim financial statements include all adjustments, which in the opinion of management, are necessary in order to make the financial statements not misleading.

CONSOLIDATED BALANCE SHEETS

	(Unaudited) October 31 2001 Restated	July 31 2001 Restated
ASSETS	(Note 2)	(Note 2)

Current Assets		
Cash and cash equivalents	\$ 101,917	\$ 207,092
Accounts receivable, net of allowance for doubtful accounts of \$ 100,000 at October 2001 and \$115,000 at July 31, 2001	534,177	570,733
Due from officers and employees	256,936	240,001
Inventories	621,439	711,018
Prepaid expenses	176,799	182,556
	-----	-----
Total current assets	1,691,268	1,911,400
	-----	-----
Property, Plant and Equipment		
Property, plant and equipment	842,192	903,072
	-----	-----
Total property, plant and equipment	842,192	903,072
	-----	-----
Noncurrent Assets		

Edgar Filing: INNOVATIVE MEDICAL SERVICES - Form 10QSB/A

Deposits	8,127	8,127
Patents and licenses	1,071,704	1,014,282
	-----	-----
Total noncurrent assets	1,079,831	1,022,409
	-----	-----
Total assets	\$ 3,613,291	\$ 3,836,881
	=====	=====
LIABILITIES AND STOCKHOLDERS EQUITY		
Current Liabilities		
Accounts payable	\$ 351,043	\$ 543,992
Accrued liabilities	106,368	96,691
Notes payable	300,000	-
	-----	-----
Total current liabilities	757,411	640,683
	-----	-----
Stockholders' Equity		
Common stock, no par value: authorized 20,000,000 shares, issued and outstanding 6,974,699 at October 31, 2001 and 6,954,699 at July 31, 2001	11,670,446	11,619,665
Accumulated deficit	(8,814,566)	(8,423,467)
	-----	-----
Total stockholders' equity	2,855,880	3,196,198
	-----	-----
Total liabilities and stockholders' equity	\$ 3,613,291	\$ 3,836,881
	=====	=====

CONSOLIDATED STATEMENTS OF INCOME (Unaudited)

For The Three Months Ended	
October 31	

2001	2000
Restated	

Edgar Filing: INNOVATIVE MEDICAL SERVICES - Form 10QSB/A

	(Note 2)	
	-----	-----
Net sales	\$ 864,028	\$ 366,126
Cost of sales	487,864	164,077
	-----	-----
Gross profit	376,164	202,049
	-----	-----
Selling expenses	234,409	174,518
General and administrative expenses	459,953	445,473
Research and development	70,823	50,985
	-----	-----
Total operating costs	765,185	670,976
	-----	-----
Operating income (loss)	(389,021)	(468,927)
	-----	-----
Other income and (expense):		
Interest income	212	14,599
Interest Expense	(1,690)	-
	-----	-----
Total other income (expense)	(1,478)	14,599
	-----	-----
Income (loss) before income taxes, minority interest in subsidiary operations	(390,499)	(454,328)
Federal and state income taxes	600	200
	----	----
Income (loss) before minority interest in subsidiary operations	(391,099)	(454,528)
Minority interest in subsidiary operations	-	14,972
	-----	-----
Net income (loss)	\$ (391,099)	\$ (439,556)
	=====	=====
Net income (loss) per common share (basic)	\$ (0.06)	\$ (0.07)
	=====	=====
Net income (loss) per common share (diluted)	\$ (0.06)	\$ (0.07)
	=====	=====

CONSOLIDATED STATEMENTS OF ACCUMULATED DEFICITS

	Three Months Ended October 31	Year Ended July 31

Edgar Filing: INNOVATIVE MEDICAL SERVICES - Form 10QSB/A

	2001	2001
	-----	-----
Balance, beginning of period	\$ (8,423,467)	\$ (6,411,971)
Net income (loss)	(391,099)	(2,011,496)
	-----	-----
Balance, end of period	\$ (8,814,566)	\$ (8,423,467)
	=====	=====

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

	For The Three Months October 31	
	2001	2002
	Restated (Note 2)	(Note 2)
	-----	-----
Cash flows from operating activities		
Net income (loss)	\$ (391,099)	\$ (4,011,496)
Adjustments to reconcile net income to net cash provided by operating activities:		
Amortization	14,165	
Depreciation	67,315	
Minority interest in subsidiary operations	-	
Changes in assets and liabilities:		
(Increase) decrease in restricted cash	-	
(Increase) decrease in accounts receivable	36,556	
(Increase) decrease in due from officers and employees	(16,935)	
(Increase) decrease in prepaid expense	5,757	
(Increase) decrease in inventory	89,579	
(Increase) decrease in deposits	-	
Increase (decrease) in accounts payable	(192,949)	
Increase (decrease) in accrued liabilities	9,679	
	-----	-----
Net cash provided (used) by operating activities	(377,932)	(3,011,496)
Cash flows from investing activities		
Purchase of property, plant and equipment	(6,434)	
Purchase of patents and licenses	(71,589)	
Deferred acquisition costs	-	
	-----	-----
Net cash (used) in investing activities	(78,023)	(2,011,496)
	-----	-----

Edgar Filing: INNOVATIVE MEDICAL SERVICES - Form 10QSB/A

Cash flows from financing activities		
Proceeds from debt obligations	300,000	
Payments on debt obligations	-	
Proceeds from sale of common stock	50,780	

Net cash provided by financing activities	350,780	

Net increase (decrease) in cash and cash equivalents	(105,175)	(5)
Cash at beginning of period	207,092	1,1

Cash at end of period	\$ 101,917	\$ 6
	=====	=====
Supplemental disclosures of cash flow information		
Cash paid for interest paid	\$ 1,690	\$
Cash paid for taxes paid	\$ 2,400	\$
Noncash investing and financing activities:		
Value of shares issued in exchange for Nutripure.com minority interest	\$ -	\$ 5

NOTES TO FINANCIAL STATEMENTS

Note 1. Financial Statements

The financial statements included herein have been prepared by Innovative Medical Services (the Company) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted as allowed by such rules and regulations, and Innovative Medical Services believes that the disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the July 31, 2001 audited financial statements and the accompanying notes thereto. While management believes the procedures followed in preparing these financial statements are reasonable, the accuracy of the amounts are in some respects dependent upon the facts that will exist and procedures that will be accomplished by Innovative Medical Services later in the year. The results of operations for the interim periods are not necessarily indicative of the results of operations for the full year.

Note 2. Restatement of Financial Statements - Start-up Costs and Warranty Liability

The accompanying financial statements have been restated to correct an error in the recording and reporting of Start-up Costs and the Warranty Liability of the Company.

The Company expended \$230,000 during the year ended July 31, 2001

Edgar Filing: INNOVATIVE MEDICAL SERVICES - Form 10QSB/A

and an additional \$47,831 during the July 31, 2002 fiscal year in an effort to acquire and setup a Korean corporation. The Company capitalized these costs as Deferred Acquisition costs as incurred. The Company later determined the venture was not feasible and decided not to go forward with the project. The total costs of \$277,831 were written-off as Abandoned Projects at July 31, 2002. We now believe the treatment of these costs was not correct. The accompanying financial statements now show these costs as expensed when incurred as Start-up Costs. The income statement effect of this restatement was to increase the net loss at July 31, 2001 by \$230,000 and to decrease the net loss at July 31, 2002 by \$230,000. The balance sheet effect is to show a decrease in Deferred Acquisition Costs ay July 31, 2001 of \$230,000.

In previous years the Company had not recorded a liability for its future warranty obligation. Because the Company has now computed and booked this liability the accompanying financial statements have been restated to include this obligation. A liability of \$43,817 at October 31, 2001 and \$33,791 at July 31, 2001 are now included in Accrued Liabilities. The income statement effect of these items was to reduce net loss at July 31, 2001 by \$729 and to increase net loss for the quarter ended October 31, 2001 \$10,027.

Note 3. Segment Information

In accordance with the provisions of SFAS No. 131, certain information is disclosed based on the way management organizes financial information for making operating decisions and assessing performance. In determining operating segments, the Company reviewed the current management structure reporting to the chief operating decision-maker ('CODM') and analyzed the reporting the CODM receives to allocate resources and measure performance.

The Company's business activities are divided, managed and conducted in two basic business segments, the Water Treatment segment and the Bio Sciences segment. These two segments were determined by management based upon the inherent differences in the end use of the products, the inherent differences in the value added processes made by the Company, the differences in the regulatory requirements and the inherent differences in the strategies required to successfully market finished products.

The Company plans to utilize multiple forms of analysis and control to evaluate the performance of the segments and to evaluate investment decisions. In general, gross margin and Earnings Before Interest Depreciation and Amortization (EBITDA) are deemed to be the most significant measurements of performance, although collection volumes and certain controllable costs also provide useful "early warning signs" of future performance. Because the Company has just recently changed to multiple segments, historical data on gross profit and income from operations is not available. However, the following is a summary of segment revenues at October 31, 2001:

	Three months Ended October 31, 2000	% Total Sales	Three months En October 31, 2
Revenues:			
Water Treatment	\$ 326,200	100%	\$528,300

Edgar Filing: INNOVATIVE MEDICAL SERVICES - Form 10QSB/A

Bioscience	0	0%	335,700
	-----	---	-----
Total Revenues	\$326,200	100%	\$864,000
	=====	====	=====

Note 4. Subsequent Events

On November 30, 2001, we settled the dispute with NVID. Under the terms of the agreement, NVID dismissed its case against us and assigned the Axenohl patent to us. In return, NVID receives 651,000 shares of our common stock and 5% of our gross Axenohl sales until March 2018, the end of the life of the patent. Innovative Medical Services issued an additional 49,000 shares to settle claims on behalf of NVID. There are minimum royalties of \$1,000,000 for the period of November 2001 to July 31, 2004 and for each fiscal year thereafter. If the minimum royalty for any period is not met, we have the right, in our sole and absolute discretion to pay NVID the deficiency in cash, in our common stock at prevailing market prices or transfer the patent back to NVID without further royalty obligation. As the sole owner of the patent, we control the granting of rights to market and distribute Axenohl and related products. ETI-H2O, our wholly owned subsidiary, retains sole manufacturing rights. As part of the settlement agreement, we have entered into non-exclusive marketing agreements for Axenohl with Watertronics, Ltd., for the United Kingdom and Aqua Biotech S.A. de C.V. for the Republic of Mexico. In addition, Innovative Medical Services reaffirmed the exclusive right of Sistecam, S.A. to manufacture and market Axenohl for sale in Costa Rica for the duration of the patent.

Note 5. Warrants

On August 8, 2001 the total 3,687,500 Class A warrants and the total 785,000 Class Z warrants expired without exercise.

Note 6. Reclassifications

Certain reclassifications have been made to previously reported statements to conform to the Company's current financial statement format.

Note 7. Line of Credit

During the quarter, the Company obtained line of credit financing with a private lender. The term of the agreement is one year beginning September 15, 2001 with an interest rate of 12% per annum. The Company may borrow up to \$500,000, which is fully secured against the Company's accounts receivables. At October 31, 2001, the Company had drawn \$300,000 against the line of credit.

ITEM 2

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Edgar Filing: INNOVATIVE MEDICAL SERVICES - Form 10QSB/A

The following discussion and analysis should be read in conjunction with the audited and unaudited financial statements of Innovative Medical Services.

OVERVIEW

Innovative Medical Services began as a provider of pharmaceutical water purification products. Although the majority of our current revenues are still from the pharmacy industry, we have expanded from our commercial pharmacy market into other, broader markets with new products, including residential water filtration systems, health and wellness related e-commerce products and bioscience technologies.

Water Treatment Division

The Fillmaster(R) pharmaceutical water purification, dispensing and measuring products include the Pharmapure(R) water purification system, the FMD 550 dispenser, the patented Fillmaster 1000e computerized dispenser and the patented Scanmaster(TM) bar code reader. We also market proprietary National Sanitation Foundation certified replacement filters for the Fillmaster Systems.

Our Nutripure(R) line of water treatment and filtration systems includes the Nutripure 3000S-Series whole-house water softening systems, the Nutripure Elite reverse osmosis point-of-use systems, the Nutripure 2000 countertop water filtration system and the Nutripure Sport filtered sport bottle. We distribute our various Nutripure products in several ways, including retail sales, catalogue placement, business-to-business sales, internet promotion and in-home sales presentations.

E-Commerce

Through our subsidiary Nutripure.com, we operate Nutripure.com(TM), an e-commerce health website that distributes Bergen Brunswig products. We provide consumers a wide variety of vitamins, minerals, nutritional supplements, homeopathic remedies and natural products. In addition to merchandise, the site offers comprehensive health and wellness information in an easy-to-access, intuitive reference format. Although sales from Nutripure.com are non-material, we have minimized costs related to the operation and promotion of the website.

Bioscience Division

Our bioscience division includes a silver ion technology called Axenohl(TM). Axenohl is a patented, non-toxic aqueous disinfectant. The use dilution formulation of Axenohl is called Axen(TM). The EPA registration for use of Axenohl and Axen as hard surface disinfectants has been issued. The first Axen-containing product we developed is our CleanKill(TM) hard surface disinfectant for sale to the pest control industry. We intend not only to sell our own Axen-based hard surface disinfectant products, but also to sell Axen as an additive to other manufacture's products

We plan to pursue additional EPA, USDA and FDA regulatory approvals for other applications. Additional possible uses for this product include wound care, topical infection care and personal disinfecting retail products, which may require FDA approvals, as well as municipal water treatment and point-of-use/point-of-entry water treatment products, which may require additional EPA approvals. The investment necessary to pursue regulatory approval for Axenohl will be significant, but as additional US and international approvals for Axenohl uses are received, we expect revenues to develop quickly.

We currently operate under a five-year contract signed in March 2001 to provide Axenohl to Dodo & Company, a Korean cosmetics manufacturer and marketer. Dodo & Company has developed an Axen-containing line of skin care products for the treatment of acne. The product line, called A-Clinic, launched in South Korea in

Edgar Filing: INNOVATIVE MEDICAL SERVICES - Form 10QSB/A

September 2001. Under the contract, Dodo & Company will purchase approximately \$1.2 million dollars of product from us over five years. In addition to the purchase price, we will receive a royalty on sales of the Axen-containing products. We anticipate that, over the five years, the revenues from Dodo & Company cosmetics royalties will exceed \$5 Million. Regulatory clearances have not been issued in South Korea.

Originally, we obtained worldwide manufacturing and marketing rights to Axen/Axenohl from NVID International, Inc., in a License Agreement dated November 24, 1999 and a Manufacturing, Licensing and Distribution Agreement dated March 26, 2000 which supersedes the November 1999 Agreement. The latter agreement became the subject of litigation that has subsequently settled in November 2001.

Under the terms of the settlement, we acquired the Axenohl patent from NVID in exchange for 700,000 shares of our common stock and 5% of our gross Axenohl sales until March 2018, the end of the life of the patent. There are minimum royalties of \$1,000,000 for the period of November 2001 to July 31, 2004 and for each fiscal year thereafter. If the minimum royalty for any period is not met, we have the right, in our sole and absolute discretion to pay NVID the deficiency in cash, in our common stock at prevailing market prices or transfer the patent back to NVID without further royalty obligation. As the sole owner of the patent, we control the granting of rights to market and distribute Axenohl and related products. ETI-H2O, our wholly owned subsidiary, retains sole manufacturing rights. As part of the settlement agreement, we have entered into non-exclusive marketing agreements for Axenohl with Watertronics, Ltd., for the United Kingdom and Aqua Biotech S.A. de C.V. for the Republic of Mexico. In addition, Innovative Medical Services reaffirmed the exclusive right of Sistecam, S.A. to manufacture and market Axenohl for sale in Costa Rica for the duration of the patent.

Our bioscience division also includes a line of pesticide technologies. The EPA-approved RoachX(TM) was the first product to launch from the line. The national kickoff took place at the National Pest Management Association meeting in New Orleans, Louisiana, in October 2001. We have earned the support of and are selling RoachX through Vopak (formerly Van, Waters & Rogers) and members of the Speckoz group of nine regional independent wholesalers.

United States Department of Agriculture testing confirms that RoachX is over 96% effective in three to four days with one application for indoor and outdoor eradication of cockroaches, and can be used near children and food preparation areas. Boric acid is a well-known and effective deterrent of cockroaches and will kill them on contact, but cockroaches do not naturally eat the repellent. Although many pesticide products contain boric acid as the listed active ingredient, we believe RoachX to be new because of the combination of boric acid and glycerin in a colloidal suspension to create three unique results: 1) The formula protects the boric acid from water and humidity, 2) The cockroaches perceive formulation as food and will actually eat the glycerin-encapsulated boric acid, and 3) The formula acts as a time-released pesticide, allowing the cockroach to return to the nest before it dies and then becomes a "bait station" for other roaches in the colony. We believe the product line, containing particular formulas for specific pests, is effective against cockroaches, ants, palmetto bugs, silverfish, waterbugs, ticks, fleas, lice and garden pests.

At the October trade show, we also launched ProChoice(TM) caulk for pest control operators. We repackage an NSF, USDA and FDA approved food-grade silicone caulk as our ProChoice product. ProChoice does not contain any pesticide and is a

Edgar Filing: INNOVATIVE MEDICAL SERVICES - Form 10QSB/A

convenience tool for pest control operators for "exclusion", or the filling of cracks and crevices to create a physical barrier insects cannot penetrate.

In January 2002, we will formally launch CleanKill(TM), the Axen-based hard surface disinfectant for the pest control industry. CleanKill is approved by the EPA as an additional brand name of Axen. We believe adding sales of these products to the already climbing RoachX revenues will have a very material positive effect on revenues in the coming fiscal year.

By February 2002, we plan to launch AntX(TM), our latest development in pesticide technology. We have submitted for and anticipate receiving EPA approval for AntX(TM), the next product in the line. We are ready to begin selling AntX as soon as approval is received.

Although we think that the pesticide technologies will have the most immediate material impact on revenues in the coming quarters, we believe that the silver ion technologies will ultimately become the largest revenue generator for Innovative Medical Services. We intend not only to sell our own Axen-based products, like CleanKill, but also to sell Axen as an additive to other manufacturer's products, like Dodo Cosmetics' acne-fighting product line. We believe that the innumerable applications for a non-toxic, tasteless, odorless, highly effective antimicrobial agent present an outstanding market opportunity for our Axenohl products.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED OCTOBER 31, 2001 VERSUS THREE MONTHS ENDED OCTOBER 31, 2001 During the quarter, we continued to realize revenues from multiple product lines in our different divisions. In order to be more informative regarding distribution of revenues, discussion of revenues will be in terms of our water treatment and bioscience divisions.

Revenues of \$864,000 in the quarter ended October 31, 2001 were 136% higher than the \$366,100 in revenues reported for the quarter ended October 31, 2000. In the prior period, revenues were exclusively from sales of commercial and residential water treatment products. In the current period, revenues were also generated from our new bioscience division. The increase in revenues was due to an increase in revenues in our water treatment division and the addition of revenues from our bioscience division. During the quarter, water treatment division revenues of \$528,400 were 42% higher than the prior quarter and include \$411,400 in Fillmaster commercial water purification product sales and \$117,000 in Nutripure residential water treatment product sales. Bioscience division revenues were \$335,600 and include silver ionization product sales of \$210,000 and pesticide product sales of \$125,600.

Except for products sold through the Nutripure water dealer program, revenues of all products are recognized on shipment where the sale is made F.O.B. shipping point. Nutripure water dealer program sales consist mostly of sales of other manufacturers' products to independent dealers. Revenue is recognized on sales to dealers as shipped since we currently do not sell to third party customers of the dealers.

Gross profit for the quarter ended October 31, 2001 was \$376,164 versus \$202,049 in 2000. Gross profit percentage of 44% in 2001 was lower versus 55% in 2000. The decrease in gross profit percentage was largely due to lower margins associated with the Nutripure water dealer program products. Also in the prior quarter, Fillmaster replacement filter sales, which are associated with higher margins, comprised 33% of total sales compared to only 14% of total sales in the recent quarter.

Edgar Filing: INNOVATIVE MEDICAL SERVICES - Form 10QSB/A

Net loss for the quarter ended October 31, 2001 was \$391,100 versus net loss of \$439,600 for the same period in 2000. During the quarter, General and Administrative expenses remained constant increasing only 3% or \$14,500 from \$445,500 in fiscal 2000 to \$460,000 in fiscal 2001. Selling expense increased approximately \$59,900, or 34%, from \$174,500 in 2000 to \$234,400 in 2001 because of increased costs associated with development of marketing materials, hiring of additional sales personnel, trade shows and product launches for the bioscience division. Research and Development costs were higher; increasing \$19,800 or 39% from \$51,000 in the quarter ended October 31, 2000 to \$70,800 in the current quarter. The increase was due mainly to costs associated with development of bioscience division products, including RoachX, AntX and Clean Kill.

LIQUIDITY AND CAPITAL RESOURCES

From inception through October 31, 2001, we have financed our operations primarily through our initial public offering in August of 1996, by a subsequent private placement in March of 2000, and by other smaller private placement stock sales. We have operated without long-term debt and have no plans to obtain long-term financing in the next twelve months. We believe that sales from our new product lines will not provide sufficient capital resources to sustain operations and fund product development through fiscal year 2002. In the short term, we expect to raise capital through equity sales as necessary to fund future growth until we operate above the break-even point. We continually evaluate opportunities to sell additional equity or debt securities, or obtain credit facilities from lenders to strengthen our financial position. The sale of additional equity or convertible debt securities could result in additional dilution to our stockholders.

Our liquidity is unaffected by the financing program offered to participating dealers in the Nutripure water dealer program. We receive funds from our primary lender and disperse the funds to the dealer, less a commission charged by us, upon completion of the contract. The primary lender disperses funds to us. We record a liability when the funds are received and relief of liability when funds are dispersed, and we do not retain liability on the credit extended.

During the fiscal quarter ended October 31, 2001, our current assets to liabilities ratio decreased from 3.15 to 2.37. Current assets decreased \$220,100 from \$1,911,400 to \$1,691,300. Current assets at October 31, 2001 include a decrease of \$105,200 in cash and cash equivalents and a decrease of \$89,600 in inventories, which reflects a changing product mix and more efficient purchasing. Accounts receivable and other current assets remained relatively constant.

Current liabilities increased \$106,700 from \$606,900 to \$713,600. The increase in current liabilities was the net result of a pay down of accounts payable of \$193,000 and an increase in notes payable of \$300,000. The note payable was drawn against a \$500,000 credit line we established during the quarter, which is secured against our accounts receivable.

Noncurrent assets increased by \$57,400 during the quarter due to the increase in Patents and Licenses.

Cash flows used from operations were \$377,900 in the quarter ended October 31, 2001 and \$320,200 in 2000. For fiscal 2001, cash flows used in investing activities included \$6,400 for the purchase of machinery and equipment and \$71,600 for the purchase of patents and licenses. In fiscal 2000 cash flows used in investing activities included \$21,900 for the purchase of machinery and equipment and \$34,000 for the purchase of patents and licenses. We also incurred \$201,200 in deferred acquisition costs during fiscal 2000. Cash flows from financing activities were \$350,800 in fiscal 2001 and \$70,300 in fiscal 2000.

Edgar Filing: INNOVATIVE MEDICAL SERVICES - Form 10QSB/A

Financing activities for the current quarter included the addition of \$300,000 in notes payable from a line of credit established in September 2001. Cash flows from financing activities also included an increase of common stock of \$51,000 from the exercise of options during the quarter. In the prior quarter, cash flows from financing activities included a pay down of \$14,600 in notes payable and an increase of common stock of \$84,900 from the exercise of options during the quarter. The total decrease in cash and cash equivalents for 2001 was \$105,200 as compared to an increase of \$506,900 during the same period in 2000.

SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INNOVATIVE MEDICAL SERVICES

(Registrant)

By: /s/ Michael L. Krall

Michael L. Krall, President/CEO
August 4, 2003

By: Gary Brownell

Gary Brownell, Chief Financial Officer
August 4, 2003